Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Medicare Part D Gross Spending on GLP-1s Increased Five-Fold Between 2019 and 2024, But Estimated Rebates of Around 50% Mean That Net Spending is Much Lower Gross Medicare Part D spending on GLP-1s in 2024 (not accounting for rebates) totaled $27.5 billion, a five-fold increase from 2019, reflecting an expansion in use of GLP-1s with more recent FDA approvals for type 2 diabetes
DSIP mechanism of action is still not fully characterized after 40 years
Evaluation of compliance with injection protocols and any barriers to consistent administration
Their mechanism gives them two major downstream effects of interest: improved glycemic control and weight reduction (due to appetite reduction + slower gastric emptying) plus other possible metabolic benefits
For the full safety article, read: GHK-Cu Side Effects How Long Does GHK-Cu Take to Work
Who Is a Good Candidate for Each Peptide
